Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications

被引：15

作者：

Kaur K. ^{[1
]}

Gandhi M.A. ^{[1
]}

Slish J. ^{[1
]}

机构：

[1] St John Fisher College Wegmans School of Pharmacy, Rochester, NY

来源：

Infectious Diseases and Therapy | 2015年 / 4卷 / 2期

关键词：

HCV; HIV; HIV–HCV drug interactions;

D O I：

10.1007/s40121-015-0061-2

中图分类号：

学科分类号：

摘要：

One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and mortality in HIV-HCV coinfected individuals. Optimal treatment in this patient population is critical, as coinfection has been linked to deterioration of both disease states. The objective of this review article is to highlight the current literature on drug-drug interactions between HIV and HCV treatments. The management of the treatment of coinfection patients has been covered extensively in numerous other publications. © 2015, The Author(s).

引用

页码：159 / 172

页数：13

共 37 条

[11]

Kirby B., Mathias A., Rossi S., No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. 63rd Annual Meeting of the American Association of the Study of Liver Diseases (AASLD) 2012. Nov 9–11, 2012, (2013)

[12]

Izquierdo L., Helle F., Francois C., Et al., Simeprevir for the treatment of hepatitis C virus infection, Pharmgenom Pers Med., 7, pp. 241-249, (2014)

[13]

Gilead Sciences, (2013)

[14]

Gilead Sciences, (2012)

[15]

Foster City, CA, (2012)

[16]

Gilead Sciences, (2014)

[17]

Lawitz E., Poordad F.F., Pang P.S., Et al., Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial, Lancet, 383, 9916, pp. 515-523, (2014)

[18]

Whitehouse Station, NJ, (2011)

[19]

Hulskotte E.G., Feng H.P., Xuan F., Et al., Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir, Clin Infect Dis, 56, 5, pp. 718-726, (2013)

[20]

Vertex Pharmaceuticals (Canada) Incorporated, (2013)

← 1 2 3 4 →